IFNβ Is a Potent Adjuvant for Cancer Vaccination Strategies

IFNβ Is a Potent Adjuvant for Cancer Vaccination Strategies

Cancer vaccination drives the generation of anti-tumor T cell immunity and can be enhanced by the inclusion of effective immune adjuvants such as type I interferons (IFNs). Whilst type I IFNs have been shown to promote cross-priming of T cells, the role of individual subtypes remains unclear. Here w...

Full description

Bibliographic Details
Main Authors: Katherine M. Audsley, Teagan Wagner, Clara Ta, Hannah V. Newnes, Anthony C. Buzzai, Samantha A. Barnes, Ben Wylie, Jesse Armitage, Tsuneyasu Kaisho, Anthony Bosco, Alison McDonnell, Mark Cruickshank, Vanessa S. Fear, Bree Foley, Jason Waithman
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-09-01
Series:Frontiers in Immunology
Subjects:
type I interferon
IFNβ
cancer vaccination
adjuvant
cross-priming
CD8+ T cells
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2021.735133/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2021.735133/full

Similar Items